Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Zhi Bing Liu, Luyan Zhang, Jia Bian & Jinbo Jian. (2020) Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer. OncoTargets and Therapy 13, pages 2657-2666.
Read now
Read now
Claire Vanpouille-Box, Claire Lhuillier, Lucillia Bezu, Fernando Aranda, Takahiro Yamazaki, Oliver Kepp, Jitka Fucikova, Radek Spisek, Sandra Demaria, Silvia C. Formenti, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2017) Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology 6:11.
Read now
Read now
Joe Abdo, Devendra K. Agrawal & Sumeet K. Mittal. (2017) Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Review of Anticancer Therapy 17:1, pages 33-45.
Read now
Read now
P. Queirolo, A. Morabito, S. Laurent, S. Lastraioli, P. Piccioli, P. A. Ascierto, G. Gentilcore, M. Serra, A. Marasco, E. Tornari, B. Dozin & M. P. Pistillo. (2013) Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study. Cancer Investigation 31:5, pages 336-345.
Read now
Read now
Pamela N Munster & Adil I Daud. (2011) Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opinion on Investigational Drugs 20:11, pages 1565-1574.
Read now
Read now
Dimiter V Tassev & Nai-Kong V Cheung. (2009) Monoclonal antibody therapies for solid tumors. Expert Opinion on Biological Therapy 9:3, pages 341-353.
Read now
Read now
Articles from other publishers (27)
Edward B. Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Sang-We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng-Ta Yang, Luiz Henrique Araujo, Haruhiro Saito, Niels Reinmuth, Nenad Medic, Helen Mann, Xiaojin Shi, Solange Peters, Tony Mok & Melissa Johnson. (2023) Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer 186, pages 107422.
Crossref
Crossref
Mahmood Araghi, Reza Mannani, Ali Heidarnejad maleki, Adel Hamidi, Samaneh Rostami, Salar Hozhabri Safa, Fatemeh Faramarzi, Sahar Khorasani, Mina Alimohammadi, Safa Tahmasebi & Reza Akhavan-Sigari. (2023) Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell International 23:1.
Crossref
Crossref
Wenjie Liu, Gengwei Huo & Peng Chen. (2023) First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States. Frontiers in Pharmacology 14.
Crossref
Crossref
Robert Matera & Anne Chiang. (2023) What Is New in Small Cell Lung Cancer. Hematology/Oncology Clinics of North America 37:3, pages 595-607.
Crossref
Crossref
Ahan Bhatt & Jennifer Wu. (2023) Immunotherapy for recurrent hepatocellular carcinoma. World Journal of Gastroenterology 29:15, pages 2261-2271.
Crossref
Crossref
Ying Cheng, Qing Zhou, Baohui Han, Yun Fan, Li Shan, Jianhua Chang, Si Sun, Jian Fang, Yuan Chen, Jianguo Sun, Gang Wu, Helen Mann, Kirsha Naicker, Norah Shire, Tony Mok & Gilberto de CastroJrJr. (2023) NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. Lung Cancer 178, pages 87-95.
Crossref
Crossref
Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Konstantin Laktionov, Sang-We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng-Ta Yang, Luiz Henrique Araujo, Haruhiro Saito, Niels Reinmuth, Xiaojin Shi, Lynne Poole, Solange Peters, Edward B. Garon & Tony Mok. (2022) Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study. Journal of Clinical Oncology.
Crossref
Crossref
Sadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, Masaru Wakatsuki, Asahi Takahashi, Sae Yumita, Miyuki Nakagawa, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Yoshihito Ozawa, Yohei Kawasaki, Tomoya Kurokawa, Hideki Hanaoka, Hiroshi Tsuji & Naoya Kato. (2022) Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open 12:4, pages e059779.
Crossref
Crossref
Hira Shaikh, Amir Kamran & Dulabh K Monga. (2020) Immunotherapy in gastroesophageal cancers: Current state and future directions. Journal of Oncology Pharmacy Practice 27:2, pages 395-404.
Crossref
Crossref
Yuqian Feng, Huimin Jin, Kaibo Guo, Yuying Xiang, Yiting Zhang, Wurong Du, Minhe Shen & Shanming Ruan. (2021) Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?. Frontiers in Pharmacology 12.
Crossref
Crossref
Kyusang Hwang, Jin Hwan Yoon, Ji Hyun Lee & Sukmook Lee. (2021) Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines 9:1, pages 39.
Crossref
Crossref
Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel M. van den Heuvel, Manuel Cobo, David Vicente, Alexey Smolin, Vladimir Moiseyenko, Scott J. Antonia, Sylvestre Le Moulec, Gilles Robinet, Ronald Natale, Jeffrey Schneider, Frances A. Shepherd, Sarayut Lucien Geater, Edward B. Garon, Edward S. Kim, Sarah B. Goldberg, Kazuhiko Nakagawa, Rajiv Raja, Brandon W. Higgs, Anne-Marie Boothman, Luping Zhao, Urban Scheuring, Paul K. Stockman, Vikram K. Chand & Solange Peters. (2020) Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer. JAMA Oncology 6:5, pages 661.
Crossref
Crossref
Suresh Senan, Isamu Okamoto, Gyeong-won Lee, Yuanbin Chen, Seiji Niho, Gabriel Mak, Wenliang Yao, Norah Shire, Haiyi Jiang & Byoung Chul Cho. (2020) Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Clinical Lung Cancer 21:2, pages e84-e88.
Crossref
Crossref
Johannes Maximilian Ludwig, Michael Cecchini & Hyun S. Kim. 2020. Image-Guided Interventions in Oncology. Image-Guided Interventions in Oncology
371
387
.
Paul Baverel, Lorin Roskos, Manasa Tatipalli, Nancy Lee, Paul Stockman, Maria Taboada, Paolo Vicini, Kevin Horgan & Rajesh Narwal. (2019) Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status. Clinical and Translational Science 12:5, pages 450-458.
Crossref
Crossref
Ahmad A. Tarhini, Sandra J. Lee, Xiaoxue Li, Uma N.M. Rao, Arun Nagarajan, Mark R. Albertini, Jerry W. MitchellJrJr, Stuart J. Wong, Mark A. Taylor, Noel Laudi, Phu V. Truong, Robert M. Conry & John M. Kirkwood. (2019) E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clinical Cancer Research 25:2, pages 524-532.
Crossref
Crossref
Salvatore Caponnetto, Arianna Draghi, Troels Holz Borch, Marianna Nuti, Enrico Cortesi, Inge Marie Svane & Marco Donia. (2018) Cancer immunotherapy in patients with brain metastases. Cancer Immunology, Immunotherapy 67:5, pages 703-711.
Crossref
Crossref
Kelsey M Bowman & Priya Kumthekar. (2018) Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. Future Oncology 14:4, pages 391-407.
Crossref
Crossref
Jennifer Seminerio, Kevin McGrath, Christina A. Arnold, Lysandra Voltaggio & Aatur D. Singhi. (2014) Medication-associated lesions of the GI tract. Gastrointestinal Endoscopy 79:1, pages 140-150.
Crossref
Crossref
M Millward, C Underhill, S Lobb, J McBurnie, S J Meech, J Gomez-Navarro, M A Marshall, B Huang & C B Mather. (2013) Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. British Journal of Cancer 108:10, pages 1998-2004.
Crossref
Crossref
Ahmad A. TarhiniJohn CherianStergios J. MoschosHussein A. TawbiYongli ShuaiWilliam E. GoodingCindy SanderJohn M. Kirkwood. (2012) Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma. Journal of Clinical Oncology 30:3, pages 322-328.
Crossref
Crossref
Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaira, Denis Soulieres, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari & Susan M. Domchek. (2010) Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells. Clinical Cancer Research 16:13, pages 3485-3494.
Crossref
Crossref
Sanjiv S. Agarwala & Antoni Ribas. (2010) Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors. Journal of Immunotherapy 33:6, pages 557-569.
Crossref
Crossref
. (2010) Current World Literature. Current Opinion in Obstetrics & Gynecology 22:1, pages 87-93.
Crossref
Crossref
Aaron S MansfieldSvetomir N Markovic. (2009) Novel therapeutics for the treatment of metastatic melanoma. Future Oncology 5:4, pages 543-557.
Crossref
Crossref
Vladimir Beljanski. 2009. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
4
.
Anwaar Saeed, Robin Park, Junqiang Dai, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Stephen Williamson, Azhar Saeed, Jacob Ripp, Zachary Collins, Kelly Mulvaney, Molly Shugrue, Jeanette Firth-Braun, Shrikant Anant, Andrew K. Godwin, Rashna Madan, Milind Phadnis & Weijing Sun. (2022) Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. SSRN Electronic Journal.
Crossref
Crossref